Jump to content
  • Sign Up
Scott Adams

Alvine Pharmaceuticals Doses First Patient In Phase 2B Trial For Alv003 In ... - Business Wire (Press Release)

Rate this topic

Recommended Posts

Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in ...

Business Wire (press release)

The study is currently enrolling diagnosed celiac disease patients who are symptomatic despite attempting to follow a gluten-free diet. The study will evaluate the safety and efficacy of ALV003 administered over a twelve-week period; patients must ...

and more »

View the full article

Share this post

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...